Six IPOs raised $2.3 billion this past week, including the year's largest US offering, China's logistics giant ZTO Express. ZTO priced above the range and proceeded to drop 15% on its first day, highly unusual given its pricing premium, size and origin. In fact,...read more
Ra Pharmaceuticals, which is developing small molecule therapies for rare immune disorders, raised $92 million by offering 7 million shares at $13, within the range of $12 to $14. Ra Pharmaceuticals plans to list on the Nasdaq under the symbol RARX. Credit...read more
Six companies are on the US IPO calendar to raise $2.2 billion in the week ahead, or $2.6 billion including a large SPAC. October is set to surpass September as the year's most active month for IPOs. Filing activity has slowed heading into November, as expected....read more
Ra Pharmaceuticals, which is developing small molecule therapies targeting rare blood disorders, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14....read more
US IPO Weekly Recap: BlackLine soars but 5 IPOs struggle including year's largest offering
Six IPOs raised $2.3 billion this past week, including the year's largest US offering, China's logistics giant ZTO Express. ZTO priced above the range and proceeded to drop 15% on its first day, highly unusual given its pricing premium, size and origin. In fact,...read more
Ra Pharmaceuticals prices IPO at $13, within the range
Ra Pharmaceuticals, which is developing small molecule therapies for rare immune disorders, raised $92 million by offering 7 million shares at $13, within the range of $12 to $14. Ra Pharmaceuticals plans to list on the Nasdaq under the symbol RARX. Credit...read more
US IPO Week Ahead: China's ZTO Express delivers largest IPO of 2016 in a 6-deal week
Six companies are on the US IPO calendar to raise $2.2 billion in the week ahead, or $2.6 billion including a large SPAC. October is set to surpass September as the year's most active month for IPOs. Filing activity has slowed heading into November, as expected....read more
Rare blood disorder biotech Ra Pharmaceuticals sets terms for $75 million IPO
Ra Pharmaceuticals, which is developing small molecule therapies targeting rare blood disorders, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14....read more